Big Oil & Gas Names Chevron, Hess, Exxon Mobil Shares Up Today: What’s Going On?
Bernstein analyst Bob Brackett revised the rating on several oil majors following their earnings release.
Dental Firm Envista Q3 Performance Disappoints, Uncertainty, Macro Headwinds To In Short Term
Wednesday, after close, Envista Holdings Corporation (NYSE: NVST) reported Q3<
Analysts Downgrade Paycom Software Stock After Inferior Outlook, Stock Loses ~40%
Piper Sandler analyst Arvind Ramnani downgraded Paycom Software Inc (NYSE: PAYC) from Overweight to Neutral and lowered the
Paycom Stock Is Plunging Wednesday: What’s Going On?
Paycom Software Inc (NYSE: PAYC) shares are tumbling Wednesday after the company reported disappointing top-line results and issued weak guidance.
Real Estate REITs Pressured Amid Higher Interest Rate & Supply Woes, But Analyst Upgrades AvalonBay Communities: Here’s Why
Piper Sandler analyst Alexander Goldfarb revised ratings on several real estate REITs amid higher interest rates environment and increased supply pressures scenario.
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to
Cisco’s Outlook And Sales Dip Concerns – This Analyst Downgrades Stock Ahead Of Q1
Raymond James analyst Simon Leopold downgraded Cisco Systems Inc (NASDAQ: CSCO) to
Yet Another Stock Downgrade For Datadog – Analyst Sees Optimization Challenges Amis High Growth Expectations
Baird analyst William Power downgraded Datadog Inc (NASDAQ: DDOG) from Outperform to Neutral and lowered the
Datadog’s FY24 Revenue Consensus Do Not Align With Management’s Historical Guidance Trends – This Analyst Downgrades Stock
Wells Fargo analyst Andrew Nowinski downgraded Datadog Inc (NASDAQ: DDOG) from Overweight to Equal-Weight and lowered the price target
Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook
Bristol-Myers Squibb Co (NYSE: BMY) shares are trading lower on continuous weakness following the disappointing Q3 earnings and a downward revision to the